Miscellaneous and Experimental Agents

摘要: Current therapeutic approaches to postmenopausal bone loss or established osteoporosis vary widely among the different regions of world. Because no treatment has unequivocally demonstrated full prevention appearance recurrence axial peripheral fractures so far, many investigational compounds are being developed. Anabolic steroids act mainly as inhibitors resorption with very few, if any, effects on formation. high occurrence signs virilization and weak structure, risk/benefit ratio in should be considered at least problematic. If ongoing large-scale trials confirm expected benefits estrogen antagonist/agonists skeleton cardiovascular risk women optimal uterine safety, these substances likely become most prominent alternative hormonal replacement therapy after menopause. Additional studies requested evaluate potential benefit growth hormone insulin-like factors osteoporosis. Ipriflavone acts predominantly an inhibitor resorption. To efficacy ipriflavone vertebral its mineral density osteoporosis, a large multicentric European study is conducted. Treatment parathyroid peptides induces significant gain mass, skeleton. Long-term that compare peptides, doses, regimes needed better understand exact position Prolonged administration strontium osteoporotic resulted decoupling between formation yielded increase lumbar spine treated subjects. In view promising results excellent tolerance during preliminary trials, additional investigations this compound promptly initiated. Several other have been punctually suggested for early stages development. Finally, besides pharmacologic hip may also reduced by use protectors.